Norfolk research company plans clinical trials using medical marijuana
Eighteen months after receiving a broad federal license for importing medical cannabis, a Norfolk research company is about to embark on a series of critical studies into a variety of medical and mental disorders, diseases and conditions.
Sanyal Biotechnology is already considering proposals for research campuses and planning its first clinical trial for this summer. The new venture potentially opens the door to significantly expanding national research being done on the medical benefits of cannabis. Read the full story here.
Stories you may be interested in
Medical Marijuana a Hit With Seniors
In a new survey, those who turned to it for treating chronic pain reported it reduced pain and decreased the need for opioid painkillers. Nine out of 10 liked it so much they said they’d recommend medical pot to others. “I was on Percocet and replaced it with medical marijuana. Thank you, thank you, thank you,” said one senior. Another patient put…
Read More 
Cannabis and Seniors
As more and more research comes out regarding the medical benefits of cannabis, it’s important to keep up with new research as it becomes available. Here at Arfinn Med, we constantly review new studies and look at our own deidentified efficacy data to try to find any additional insights we can relay to our registered…
Read More 
Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease
A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More 
Are You Prepared For Questions About Medical Cannabis?
With over 85% of Americans supporting legalizing medical cannabis, it’s inevitable that patients will begin asking their primary care doctors about its use and overall efficacy. Doctors and other medical professionals will be called upon to be ‘sense-makers’ for a treatment they never studied in medical school and have limited available research to draw upon. …
Read More 
Dr. Sanjay Gupta on medical marijuana: We are in an age of wisdom, but also an age of foolishness
When we released “Weed” in 2013, few people had ever heard of cannabidiol, or CBD. Now, two-thirds of Americans are familiar with the compound, and 1 in 7 have tried it. Most of the country, 93%, are in favor of medical marijuana and hemp-derived CBD itself, which has less than 0.3% THC, has been legalized in every state.It’s…
Read More 
Arfinn Med Patient Site
We get a lot of interest from patients asking about efficacy data for medical marijuana on a number of conditions. Though we are primarily an electronic medical record (EMR) company focussing on the cannabis industry and other complimentary or alternative therapies, our primary focus is better quality care for patients. So with that being said,…
Read More